drugset / Trial / NCT06326346
GIST Oral Paclitaxel(Liporaxel)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Oral |